NASDAQ:KNSA Kiniksa Pharmaceuticals Q1 2025 Earnings Report $20.21 -0.32 (-1.56%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$20.21 0.00 (0.00%) As of 04/17/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Kiniksa Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.06Beat/MissN/AOne Year Ago EPSN/AKiniksa Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKiniksa Pharmaceuticals Announcement DetailsQuarterQ1 2025Date4/22/2025TimeBefore Market OpensConference Call DateTuesday, April 22, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Kiniksa Pharmaceuticals Earnings HeadlinesEvercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)April 16 at 11:20 PM | markets.businessinsider.comWedbush Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)April 16 at 11:20 PM | markets.businessinsider.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 19, 2025 | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and Tourmaline Bio (TRML)April 11, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $37.17 Average Target Price from BrokeragesApril 10, 2025 | americanbankingnews.com3 No-Brainer Healthcare Stocks to Buy With $1,000 Right NowMarch 14, 2025 | fool.comSee More Kiniksa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiniksa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals and other key companies, straight to your email. Email Address About Kiniksa PharmaceuticalsKiniksa Pharmaceuticals (NASDAQ:KNSA), a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.View Kiniksa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
